Bristol-Myers Squibb Net Income 2006-2018 | BMY

Bristol-Myers Squibb annual/quarterly net income history and growth rate from 2006 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Bristol-Myers Squibb net income for the quarter ending September 30, 2018 was $1.901B, a 124.97% increase year-over-year.
  • Bristol-Myers Squibb net income for the twelve months ending September 30, 2018 was $1.432B, a 66.14% decline year-over-year.
  • Bristol-Myers Squibb annual net income for 2017 was $1.007B, a 77.41% decline from 2016.
  • Bristol-Myers Squibb annual net income for 2016 was $4.457B, a 184.79% increase from 2015.
  • Bristol-Myers Squibb annual net income for 2015 was $1.565B, a 21.91% decline from 2014.
Bristol-Myers Squibb Annual Net Income
(Millions of US $)
2017 $1,007
2016 $4,457
2015 $1,565
2014 $2,004
2013 $2,563
2012 $1,959
2011 $3,701
2010 $3,090
2009 $10,594
2008 $5,247
2007 $2,165
2006 $1,585
2005 $3,000
Bristol-Myers Squibb Quarterly Net Income
(Millions of US $)
Q3 2018 $1,901
Q2 2018 $373
Q1 2018 $1,486
Q4 2017 $-2,328
Q3 2017 $845
Q2 2017 $916
Q1 2017 $1,574
Q4 2016 $894
Q3 2016 $1,202
Q2 2016 $1,166
Q1 2016 $1,195
Q4 2015 $-197
Q3 2015 $706
Q2 2015 $-130
Q1 2015 $1,186
Q4 2014 $13
Q3 2014 $721
Q2 2014 $333
Q1 2014 $937
Q4 2013 $726
Q3 2013 $692
Q2 2013 $536
Q1 2013 $609
Q4 2012 $924
Q3 2012 $-711
Q2 2012 $645
Q1 2012 $1,101
Q4 2011 $850
Q3 2011 $967
Q2 2011 $900
Q1 2011 $984
Q4 2010 $471
Q3 2010 $949
Q2 2010 $927
Q1 2010 $743
Q4 2009 $8,007
Q3 2009 $966
Q2 2009 $983
Q1 2009 $638
Q4 2008 $1,244
Q3 2008 $2,578
Q2 2008 $764
Q1 2008 $661
Q4 2007 $-89
Q3 2007 $858
Q2 2007 $706
Q1 2007 $690
Q4 2006 $-134
Q3 2006 $338
Q2 2006 $667
Q1 2006 $714
Q4 2005 $499
Q3 2005 $964
Q2 2005 $1,004
Q1 2005 $533
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $85.837B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
AbbVie (ABBV) United States $132.702B 11.78
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80